Published

23andMe to cut 40% of workforce, end therapeutics program

  • Genetic-Testing company 23andMe will reduce its workforce by 40% and discontinue its therapeutics program to focus on its core consumer business.
  • Approximately 200 employees will be affected, leading to expected annual savings of $35 million.
  • Ms. Wojcicki stated, "We are taking these difficult but necessary actions as we restructure 23andMe...
Insights by Ground AI
Does this summary seem wrong?
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 63% of the sources are Center
63% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)